Tirzepatide While semaglutide has a half-life of approximately 7 days supporting once-weekly dosing, tirzepatide (a dual GLP-1 and GIP receptor agonist) has a similar half-life of about 5 days
These changes are not inevitable, and they are certainly not permanent
It's worth noting that type 2 diabetes itself is associated with an increased fracture risk despite often normal or higher bone mineral density, which may complicate the interpretation of bone health outcomes in this population
This variability affects public coverage, too
Heres what I actually pay attention to when Im testing something like a GLP-1-style patch: Cravings timing: Do cravings hit at the same time every day
and urine glucose levels', Clinical Chimic Acta , 4, 395-400